New findings show potential for liquid biopsy to expand access to personalized treatment prediction in advanced NSCLC
Study suggests biologically grounded predictions could reduce safety-related failures in combination therapies in drug development and clinical care settings
Patients with TP53, KRAS, and CD274 aberrations showed decreased chemotherapy benefit, while ATM and ATR variants were linked to increased chemo-immunotherapy sensitivity
Novel Model Integrating TME Composition with TLS Gene Signatures Predicts Meaningful Survival Differences in Checkpoint Inhibitor-Treated Patients
New Study Introduces a Personalized Therapy Selection Approach in NSCLC Poised to Transform Treatment Decisions
Every cancer patient’s disease is as unique as their DNA. Each person’s cancer harbors a distinct set of genomic aberrations that can block the effectiveness of some treatments, heighten responsiveness to others, or necessitate entirely different approaches. Beyond genetic variations, additional factors such as epigenetic modifications, tumor microenvironment dynamics, and immune system interactions contribute to the unpredictability of cancer progression and therapy response.
Novel Genomic Signatures Linked to Poor ICI Response in MSI-H Cancer Patients Enable Personalized Treatment Strategies
Leptomeningeal metastasis, also known as malignant meningitis and referred to as “Lepto” or “LMD” amongst oncologists, is a life-threatening complication of cancers which have spread to the meningeal lining of the brain and spinal cord. LMD can come from cancers arising in the brain or elsewhere in the body and is relatively uncommon, arising in 3 to 5% of patients with common metastatic malignancies like lung cancer, breast cancer, and melanoma.